Amarin (AMRN) Corporation highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with diabetes and other risk factors, patients treated with Vascepa/Vazkepa experienced fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN:
- Amarin reports Q4 non-GAAP EPS 1c vs. (2c) last year
- Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities
- Amarin issues call to action for American Heart Month
- AMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amarin comments on recent innovations for patients with elevated triglycerides